3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
27
Phase 3
8
Phase 2
6
Phase EARLY_PHASE1
2
Phase 4
1
Phase 2/3
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Genitourinary
1
Breast
1
Conditions
Neoplasms
3
Stomach Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Breast Neoplasms
2
Prostatic Neoplasms
1
Peritoneal Neoplasms
1
Pancreatic Neoplasms
1
Muscular Atrophy
1
Mouth Neoplasms
1
Lymphoma, Follicular
1
Liver Neoplasms
1
Hemorrhage
1
Hematologic Neoplasms
1
Glioblastoma
1
Gallbladder Neoplasms
1
Colonic Neoplasms
1
Child Nutrition Disorders
1
COVID-19
1
Interventions
Docetaxel
7
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
5
Prednisone
5
Androgen Antagonists
5
gallium 68 PSMA-11
4
enzalutamide
3
bicalutamide
3
Triptorelin Pamoate
3
Radiosurgery
3
Leuprolide
3
Goserelin
3
2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid
3
abiraterone
2
Zoledronic Acid
2
Radiotherapy, Intensity-Modulated
2
Radiotherapy
2
Mitoxantrone
2
Flutamide
2
Celecoxib
2
Abiraterone Acetate
2
satraplatin
1
relugolix
1
pertuzumab
1
nilutamide
1
maltodextrin
1
luprolide acetate gel depot
1
histrelin
1
genistein combined polysaccharide
1
fluciclovine F-18
1
darolutamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2/3
×
Prostatic Neoplasms
×
Standard of Care
×
Clear all
NCT02759783
2019-08-21
CORE
Royal Marsden NHS Foundation Trust
Phase 2/3
Unknown
245 enrolled